Login to Your Account

Biotech keeps up its steady pace on the capital markets

Monday, February 24, 2014

As we enter the final trading week of February, public biotech companies are maintaining their relentless performance on the capital markets. The BioWorld Blue Chip Index, for example, is up almost 20 percent in value since the start of the new year. The price-weighted index that includes many of the industry’s leading biotechnology companies outperformed the Dow Jones Industrial average, which recorded a 3 percent drop and the Nasdaq Composite index, which was up 2 percent in the same period.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription